Headlines about Cellectis (NASDAQ:CLLS) have been trending positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectis earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.075306807567 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Why Cellectis SA (ADR)(NASDAQ: CLLS) stock is going gangbusters today (fxdailyreport.com)
- Nomura Increases Cellectis (CLLS) Price Target to $73.00 (americanbankingnews.com)
- Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor (finance.yahoo.com)
- Cellectis SA.’s (NASDAQ:CLLS) Profit Outlook (finance.yahoo.com)
- Cellectis Reports 4th Quarter and Full Year 2017 Financial Results (finance.yahoo.com)
A number of equities analysts have issued reports on the company. BidaskClub cut Cellectis from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Nomura increased their price objective on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Oppenheimer restated an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research note on Thursday, December 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Cellectis presently has an average rating of “Buy” and a consensus target price of $42.67.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://baseballnewssource.com/2018/03/14/favorable-press-coverage-somewhat-unlikely-to-affect-cellectis-clls-stock-price/1972022.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.